Theranexus (EPA:ALTHX) | WebDisclosure

PRESS RELEASE

published on 04/29/2024 at 18:20, 1 year 7 months ago

THERANEXUS PUBLISHES ITS 2023 FULL-YEAR RESULTS AND PRESENTS ITS PROGRESS REPORT
Theranexus reports 2023 financial results, cash position, progress report, and the arrival of Christine Placet as CFO. Highlights include positive Batten-1 trial results and funding options for future trials

Financial Results Theranexus Rare Neurological Diseases Christine Placet Batten-1 Trial
BRIEF

published on 04/29/2024 at 18:05, 1 year 7 months ago

Theranexus annonce ses résultats annuels 2023 et les avancées de ses projets

Biotechnologie Résultats Financiers 2023 Maladies Rares Theranexus Phase De Recherche
BRIEF

published on 04/29/2024 at 18:05, 1 year 7 months ago

Theranexus announces its 2023 annual results and the progress of its projects

Biotechnology 2023 Financial Results Rare Diseases Theranexus Research Phase
PRESS RELEASE

published on 04/29/2024 at 18:00, 1 year 7 months ago

THERANEXUS PUBLIE SES RESULTATS ANNUELS 2023 ET FAIT LE POINT SUR SES ACTIVITÉS
Theranexus, société biopharmaceutique à lyon, publie ses résultats annuels 2023, sa trésorerie 31 mars 2024 et ses activités. Nouvelle Directrice administrative et financière. Projets innovants dans maladies neurologiques rares

Résultats Annuels Trésorerie Theranexus Maladies Neurologiques Rares Christine Placet
BRIEF

published on 04/26/2024 at 18:05, 1 year 7 months ago

Theranexus publie ses informations sur les droits de vote et le capital pour mars 2024

Droits De Vote Capital Social Biopharmaceutique Theranexus Neurologie
BRIEF

published on 04/26/2024 at 18:05, 1 year 7 months ago

Theranexus releases voting rights and capital information for March 2024

Share Capital Voting Rights Biopharmaceutical Neurology Theranexus
PRESS RELEASE

published on 04/26/2024 at 18:00, 1 year 7 months ago

Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital
Theranexus publie le nombre d'actions et de droits de vote au 31 mars 2024, renforçant sa transparence. Détails sur son engagement dans le traitement des maladies neurologiques rares

Droits De Vote Capital Social Biopharmaceutique Theranexus Maladies Neurologiques Rares
BRIEF

published on 04/23/2024 at 07:35, 1 year 7 months ago

Theranexus, Diverchim et l'INSERM obtiennent un financement de 4.7 millions d'euros pour le développement d'un nouvel oligonucléotide antisens

Financement France 2030 Oligonucléotide Antisens Maladies Rares Neurologiques Autophagie Biothérapies
BRIEF

published on 04/23/2024 at 07:35, 1 year 7 months ago

Theranexus, Diverchim and INSERM obtain funding of 4.7 million euros for the development of a new antisense oligonucleotide

Biothérapies France 2030 Funding Antisense Oligonucleotide Rare Neurological Diseases Autophagy
PRESS RELEASE

published on 04/23/2024 at 07:30, 1 year 7 months ago

Theranexus, Diverchim et l'INSERM bénéficient d'un financement de 4.7 millions d'euros dans le cadre de l'appel à projets " Innovations en Biothérapies et Bioproduction " de France 2030, pour développer un nouvel oligonucléotide antisens
Theranexus, Diverchim, and ARNA laboratory of INSERM receive 4.7 million euros from the French government to develop a groundbreaking autophagy activation therapy called PickASO

Theranexus Diverchim ARNA Laboratory Autophagy Activation Therapy PickASO

Published on 12/05/2025 at 02:35, 7 hours 1 minute ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 7 hours 6 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 8 hours 36 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 10 hours 31 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 10 hours 36 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

Published on 12/05/2025 at 09:05, 31 minutes ago

Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 09:00, 36 minutes ago

Original-Research: DEMIRE AG (von NuWays AG): BUY
Published on 12/05/2025 at 09:00, 36 minutes ago

SPECTRIS PLC - Removal
Published on 12/05/2025 at 09:00, 36 minutes ago

Official List Notice
Published on 12/05/2025 at 09:00, 36 minutes ago

Petershill Partners plc - Removal

View all EQS

Published on 12/05/2025 at 08:45, 51 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 51 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 54 minutes ago

ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 15 hours 21 minutes ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 15 hours 36 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025

View all LES ECHOS COMFI WIRE

News